These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 38664825)

  • 21. Suppression of poised oncogenes by ZMYND8 promotes chemo-sensitization.
    Mukherjee S; Adhikary S; Gadad SS; Mondal P; Sen S; Choudhari R; Singh V; Adhikari S; Mandal P; Chaudhuri S; Sengupta A; Lakshmanaswamy R; Chakrabarti P; Roy S; Das C
    Cell Death Dis; 2020 Dec; 11(12):1073. PubMed ID: 33323928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KDM6B Counteracts EZH2-Mediated Suppression of
    Wang W; Lim KG; Feng M; Bao Y; Lee PL; Cai Y; Chen Y; Zhang H; Marzese D; Hoon DSB; Yu Q
    Mol Cancer Ther; 2018 Sep; 17(9):1973-1983. PubMed ID: 29925528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer.
    Sun L; Burnett J; Gasparyan M; Xu F; Jiang H; Lin CC; Myers I; Korkaya H; Liu Y; Connarn J; He H; Zhang N; Wicha MS; Sun D
    Oncotarget; 2016 Aug; 7(32):51408-51422. PubMed ID: 27285982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells.
    Lombardo Y; Faronato M; Filipovic A; Vircillo V; Magnani L; Coombes RC
    Breast Cancer Res; 2014 Jun; 16(3):R62. PubMed ID: 24919951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer.
    Wu X; Zahari MS; Renuse S; Nirujogi RS; Kim MS; Manda SS; Stearns V; Gabrielson E; Sukumar S; Pandey A
    Mol Cell Proteomics; 2015 Nov; 14(11):2887-900. PubMed ID: 26330541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ANLN-induced EZH2 upregulation promotes pancreatic cancer progression by mediating miR-218-5p/LASP1 signaling axis.
    Wang A; Dai H; Gong Y; Zhang C; Shu J; Luo Y; Jiang Y; Liu W; Bie P
    J Exp Clin Cancer Res; 2019 Aug; 38(1):347. PubMed ID: 31395079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genome-wide expression analysis reveals six contravened targets of EZH2 associated with breast cancer patient survival.
    Kumari K; Das B; Adhya AK; Rath AK; Mishra SK
    Sci Rep; 2019 Feb; 9(1):1974. PubMed ID: 30760814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.
    Asaduzzaman M; Constantinou S; Min H; Gallon J; Lin ML; Singh P; Raguz S; Ali S; Shousha S; Coombes RC; Lam EW; Hu Y; Yagüe E
    Breast Cancer Res Treat; 2017 Jun; 163(3):461-474. PubMed ID: 28341962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuropilin-1 promotes the oncogenic Tenascin-C/integrin β3 pathway and modulates chemoresistance in breast cancer cells.
    Naik A; Al-Yahyaee A; Abdullah N; Sam JE; Al-Zeheimi N; Yaish MW; Adham SA
    BMC Cancer; 2018 May; 18(1):533. PubMed ID: 29728077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The mitotic kinase Aurora--a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα(+) breast cancer cells.
    D'Assoro AB; Liu T; Quatraro C; Amato A; Opyrchal M; Leontovich A; Ikeda Y; Ohmine S; Lingle W; Suman V; Ecsedy J; Iankov I; Di Leonardo A; Ayers-Inglers J; Degnim A; Billadeau D; McCubrey J; Ingle J; Salisbury JL; Galanis E
    Oncogene; 2014 Jan; 33(5):599-610. PubMed ID: 23334326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mesenchymal stem cell-derived exosomal microRNA-133b suppresses glioma progression via Wnt/β-catenin signaling pathway by targeting EZH2.
    Xu H; Zhao G; Zhang Y; Jiang H; Wang W; Zhao D; Hong J; Yu H; Qi L
    Stem Cell Res Ther; 2019 Dec; 10(1):381. PubMed ID: 31842978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of EZH2 and SUZ12 Regulated by E2F1 Predicts the Disease Progression and Aggressive Characteristics of Bladder Cancer.
    Lee SR; Roh YG; Kim SK; Lee JS; Seol SY; Lee HH; Kim WT; Kim WJ; Heo J; Cha HJ; Kang TH; Chung JW; Chu IS; Leem SH
    Clin Cancer Res; 2015 Dec; 21(23):5391-403. PubMed ID: 26268246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2.
    Rizzo S; Hersey JM; Mellor P; Dai W; Santos-Silva A; Liber D; Luk L; Titley I; Carden CP; Box G; Hudson DL; Kaye SB; Brown R
    Mol Cancer Ther; 2011 Feb; 10(2):325-35. PubMed ID: 21216927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epithelial-mesenchymal transition and cancer stem cell interactions in breast phyllodes tumours: immunohistochemical evaluation of EZH2, EZR, HMGA2, CD24 and CD44 in correlation with outcome analysis.
    Ahmed SS; Lim JCT; Thike AA; Iqbal J; Tan PH
    J Clin Pathol; 2022 May; 75(5):316-323. PubMed ID: 33627375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NOP2 facilitates EZH2-mediated epithelial-mesenchymal transition by enhancing EZH2 mRNA stability via m5C methylation in lung cancer progression.
    Yang Y; Fan H; Liu H; Lou X; Xiao N; Zhang C; Chen H; Chen S; Gu H; Liu H; Wan J
    Cell Death Dis; 2024 Jul; 15(7):506. PubMed ID: 39013911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. n-Butylidenephthalide Regulated Tumor Stem Cell Genes EZH2/AXL and Reduced Its Migration and Invasion in Glioblastoma.
    Yen SY; Chuang HM; Huang MH; Lin SZ; Chiou TW; Harn HJ
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long non‑coding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway.
    Li Z; Yu D; Li H; Lv Y; Li S
    Int J Oncol; 2019 Mar; 54(3):1033-1042. PubMed ID: 30628639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The EZH2-PHACTR2-AS1-Ribosome Axis induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer.
    Chu W; Zhang X; Qi L; Fu Y; Wang P; Zhao W; Du J; Zhang J; Zhan J; Wang Y; Zhu WG; Yu Y; Zhang H
    Cancer Res; 2020 Jul; 80(13):2737-2750. PubMed ID: 32312833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells.
    Cardenas H; Zhao J; Vieth E; Nephew KP; Matei D
    Oncotarget; 2016 Dec; 7(51):84453-84467. PubMed ID: 27563817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EZH2 is regulated by ERK/AKT and targets integrin alpha2 gene to control Epithelial-Mesenchymal Transition and anoikis in colon cancer cells.
    Ferraro A; Mourtzoukou D; Kosmidou V; Avlonitis S; Kontogeorgos G; Zografos G; Pintzas A
    Int J Biochem Cell Biol; 2013 Feb; 45(2):243-54. PubMed ID: 23116973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.